Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 134 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: paroxetine Clear all
Completed Phase 4 Interventional Results available

A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression

NCT00666757
View directory record Official record
Conditions
Depression
Interventions
duloxetine, fluoxetine, citalopram, paroxetine, sertraline
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
61
States / cities
Carson, California • Irvine, California • San Diego, California + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2010 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Results available

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

NCT04437485
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions
Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 19, 2026, 10:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Structure and Function Before and After Treatment for Post-Traumatic Stress Disorder

NCT00069225
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 3 Interventional

Treatment of Panic Disorder: Long Term Strategies

NCT00000368
View directory record Official record
Conditions
Panic Disorder, Agoraphobia
Interventions
Cognitive behavior therapy, Paroxetine or other medication - algorithm used
Behavioral · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
4
States / cities
New Haven, Connecticut • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PAXIL CR Bioequivalence Study

NCT00749359
View directory record Official record
Conditions
Depressive Disorder
Interventions
Paxil CR
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
Buffalo, New York • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Aug 4, 2017 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients

NCT00581009
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Disorder
Interventions
chronobiological augmentation, sertraline, lithium, one night of sleep deprivation and two FDG PET scans
Other · Drug · Radiation
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2011
U.S. locations
2
States / cities
Irvine, California • La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 19, 2026, 10:43 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

NCT07070232
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BNT326, Pumitamig, Itraconazole, Paroxetine
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
1,438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
19
States / cities
Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Paroxetine on Smokers' Cardiovascular Response to Stress - 1

NCT00218439
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Paroxetine, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants

NCT04981704
View directory record Official record
Conditions
Healthy
Interventions
Poziotinib, Itraconazole, Phenytoin, Paroxetine
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder

NCT01681849
View directory record Official record
Conditions
PTSD
Interventions
Placebo, Paroxetine, Positron Emission Tomography (PET) Imaging
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women

NCT01829919
View directory record Official record
Conditions
Postmenopausal Symptoms
Interventions
Brisdelle (paroxetine mesylate)
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
40 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities

NCT00403455
View directory record Official record
Conditions
PTSD
Interventions
Paroxetine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 4 Interventional

Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome

NCT00610610
View directory record Official record
Conditions
Fibromyalgia Syndrome
Interventions
Paroxetine CR, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 19, 2026, 10:43 PM EDT
Recruiting No phase listed Observational

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

NCT03511118
View directory record Official record
Conditions
Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions
Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
20
States / cities
La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 19, 2026, 10:43 PM EDT
Completed No phase listed Observational

YouScript IMPACT Registry

NCT02191358
View directory record Official record
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Not listed
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 4 Interventional

Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS)

NCT00610909
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Paroxetine CR, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 4 Interventional Results available

Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study

NCT01748955
View directory record Official record
Conditions
Depression, Suicidal Ideation
Interventions
Paroxetine CR for Major Depressive Episode, Bupropion XL for Major Depressive Episode
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Stepped Care for Depression and Musculoskeletal Pain

NCT00118430
View directory record Official record
Conditions
Pain, Depression
Interventions
Stepped Care, Antidepressants, Usual Care
Behavioral · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects

NCT04650542
View directory record Official record
Conditions
Drug-drug Interaction
Interventions
HBI-3000, Paroxetine
Drug
Lead sponsor
HUYABIO International, LLC.
Industry
Eligibility
18 Years to 50 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 15, 2022 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Not applicable Interventional

Prazosin vs. Paroxetine in Combat Stress Symptoms in OIF/OEF Returnees

NCT00261729
View directory record Official record
Conditions
Sleep Disorders, Stress Disorders, Post-Traumatic
Interventions
Paroxetine, Prazosin, placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 50 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 3, 2009 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 3 Interventional Results available

Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder

NCT00074802
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Paroxetine, Cognitive behavioral therapy (CBT)
Drug · Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg

NCT00648193
View directory record Official record
Conditions
Healthy
Interventions
Paroxetine hydrochloride 40 mg tablet, Paxil® 40 mg Table
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 4 Interventional

Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study

NCT00177567
View directory record Official record
Conditions
Bipolar Disorder
Interventions
lithium carbonate, Depakote-ER, risperidone, olanzapine, paroxetine, bupropion, lamotrigine, venlafaxine, tranylcypromine, mirtazapine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2005 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment

NCT02400346
View directory record Official record
Conditions
Major Depression Disorder
Interventions
Adjunct brexpiprazole, ADT
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
65 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Arcadia, California • Miami, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 19, 2026, 10:43 PM EDT